Stockscreener 앱 받기
1.47
2.08%
0.03
시간 외 거래:
1.48
0.01
+0.68%
전일 마감가:
$1.44
열려 있는:
$1.46
하루 거래량:
79,342
Relative Volume:
0.38
시가총액:
$33.02M
수익:
-
순이익/손실:
$-58.20M
주가수익비율:
-0.5647
EPS:
-2.603
순현금흐름:
$-47.21M
1주 성능:
+5.00%
1개월 성능:
-2.00%
6개월 성능:
+32.43%
1년 성능:
-4.55%
1일 변동 폭
$1.40
$1.48
1주일 범위
$1.385
$1.49
52주 변동 폭
$0.9612
$1.68
Boundless Bio Inc Stock (BOLD) Company Profile
명칭
Boundless Bio Inc
전화
(858) 766-9912
주소
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.47 | 32.35M | 0 | -58.20M | -47.21M | -2.603 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 개시 | H.C. Wainwright | Buy |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-22 | 개시 | Guggenheim | Buy |
| 2024-04-22 | 개시 | Leerink Partners | Outperform |
| 2024-04-22 | 개시 | Piper Sandler | Overweight |
모두보기
Boundless Bio Inc 주식(BOLD)의 최신 뉴스
TradingKey - TradingKey
Number of shareholders of Boundless Bio, Inc. – NASDAQ:BOLD - TradingView
BOLD: ecDNA-targeted therapies offer a novel approach for hard-to-treat oncogene amplified cancers - TradingView
Boundless Bio Releases Q1 2026 Financial Results - AlphaStreet
Boundless Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Boundless Bio, Inc. 1Q 2026: Net income $(13.6)M, EPS $(0.60) — 10-Q Summary - TradingView
Boundless Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Boundless Bio (NASDAQ: BOLD) trims spend, ends HQ lease, guides cash into 2H 2028 - Stock Titan
Boundless Bio (Nasdaq: BOLD) Q1 2026 results and $92.8M cash runway - Stock Titan
Boundless Bio 1Q Loss/Shr 60c >BOLD - Moomoo
Cancer drug trial keeps enrolling as Boundless Bio says cash lasts to 2028 - Stock Titan
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights - Taiwan News
What BoundlessBio (BOLD) is doing that smart investors recognize (Breakout Watch) 2026-05-06Crowd Sentiment Stocks - newser.com
Boundless Bio Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
[ARS] Boundless Bio, Inc. SEC Filing - Stock Titan
Boundless Bio (NASDAQ: BOLD) details 2026 virtual meeting and pay - Stock Titan
BOLD | Boundless Bio, Inc. Common Insider Trading - Quiver Quantitative
BOLD (Boundless Bio Inc.) falls 3.07% following wider-than-expected Q4 2025 earnings per share miss.Days To Cover - Xã Thanh Hà
OGI (Organigram Global Inc. Common Shares) delivers blowout Q1 2026 results with 62 percent annual revenue growth and positive earnings.Dividend Safety - Cổng thông tin điện tử tỉnh Lào Cai
BoundlessBio (BOLD) Stock: Technical Trend Review | Boundless Bio Inc. misses EPS estimates by 9.4% on wider lossesPEG Ratio - Cổng thông tin điện tử tỉnh Lào Cai
BoundlessBio (BOLD) Stock Top Holdings (-0.32%) 2026-04-20Hot Community Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Brickell Biotech Inc (BBI) - Minichart
BoundlessBio (BOLD) Stock: Mid-Year Review (-3.07%) 2026-04-18Community Chart Signals - UBND thành phố Hải Phòng
Is Titan Machinery (TITN) stock cheap relative to fundamentals (+4.84%) 2026-04-18Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
Boundless Bio Presents Preclinical Data on BBI-940, a Novel Kinesin Degrader, at AACR Annual Meeting 2026 - Quiver Quantitative
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting - GlobeNewswire Inc.
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Tuesday's session: gap up and gap down stocks - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionAvanos Medical (NYSE:AVNS), Boundless Bio - Benzinga
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio to terminate San Diego lease, agrees to $10 million payment - Investing.com Australia
Boundless Bio Terminates Major Long-Term San Diego Lease - TipRanks
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Chipmakers Recap: Is Boundless Bio Inc in a long term uptrend2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
GODN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EPS Watch: Is Boundless Bio Inc subject to activist investor interest2026 Volume Leaders & Safe Entry Point Alerts - baoquankhu1.vn
Aug Decliners: What hedge funds are buying Akanda Corp2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Swing Trade: Is EFOI forming higher highs and higher lows2026 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is BoundlessBio (BOLD) Stock Leading the Market | Price at $1.09, Up 1.39%Parabolic SAR - Newser
NVNO PE Ratio & Valuation, Is NVNO Overvalued - Intellectia AI
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
APUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Recap: Will Boundless Bio Inc face regulatory challenges2026 WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
What analysts say about Boundless Bio Inc stockPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Boundless Bio Inc (BOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):